These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12848314)

  • 41. Sepsis. What it is and how to recognize it.
    Mileski WJ
    Surg Clin North Am; 1991 Aug; 71(4):749-64. PubMed ID: 1862469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
    Brueckmann M; Wizenmann J; Hoffmann U; Seeger M; Bewig B
    Thromb Res; 2003 Mar; 109(5-6):259-63. PubMed ID: 12818248
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic plasma exchange in severe sepsis or septic shock.
    Kes P
    Acta Med Croatica; 1998; 52(2):127-32. PubMed ID: 9682501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.
    Fourrier F; Chopin C; Goudemand J; Hendrycx S; Caron C; Rime A; Marey A; Lestavel P
    Chest; 1992 Mar; 101(3):816-23. PubMed ID: 1531791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.
    Bernard GR
    Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Coagulation disorders in septic shock.
    Thijs LG; de Boer JP; de Groot MC; Hack CE
    Intensive Care Med; 1993; 19 Suppl 1():S8-15. PubMed ID: 8227738
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.
    Dhainaut JF; Shorr AF; Macias WL; Kollef MJ; Levi M; Reinhart K; Nelson DR
    Crit Care Med; 2005 Feb; 33(2):341-8. PubMed ID: 15699837
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
    Yan SB; Nelson DR
    Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pathophysiology and therapy of sepsis-associated coagulation disorders].
    Knöbl P
    Wien Med Wochenschr; 2002; 152(21-22):559-63. PubMed ID: 12506679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Microthrombosis in sepsis.
    Vallet B
    Minerva Anestesiol; 2001 Apr; 67(4):298-301. PubMed ID: 11376528
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Controlled trial of antithrombin III supplementation in fulminant hepatic failure.
    Langley PG; Hughes RD; Forbes A; Keays R; Williams R
    J Hepatol; 1993 Mar; 17(3):326-31. PubMed ID: 8315261
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
    McCoy C; Matthews SJ
    Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.
    Vervloet MG; Thijs LG; Hack CE
    Semin Thromb Hemost; 1998; 24(1):33-44. PubMed ID: 9515778
    [TBL] [Abstract][Full Text] [Related]  

  • 55. International Society on Thrombosis and Haemostasis score for overt disseminated intravascular coagulation predicts organ dysfunction and fatality in sepsis patients.
    Voves C; Wuillemin WA; Zeerleder S
    Blood Coagul Fibrinolysis; 2006 Sep; 17(6):445-51. PubMed ID: 16905947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Sepsis-associated coagulation disorders].
    Dempfle CE
    Hamostaseologie; 2005 May; 25(2):183-9. PubMed ID: 15924156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of drotrecogin alfa (activated) in two patients with severe sepsis.
    Mikaszewska-Sokolewicz M; Nierebińska M; Mayzner-Zawadzka E
    Med Sci Monit; 2003 Aug; 9(8):CS80-7. PubMed ID: 12942037
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Coagulation system and platelets are fully activated in uncomplicated sepsis.
    Mavrommatis AC; Theodoridis T; Orfanidou A; Roussos C; Christopoulou-Kokkinou V; Zakynthinos S
    Crit Care Med; 2000 Feb; 28(2):451-7. PubMed ID: 10708182
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of the endothelium in changes in procoagulant activity in sepsis.
    Iba T; Kidokoro A; Yagi Y
    J Am Coll Surg; 1998 Sep; 187(3):321-9. PubMed ID: 9740191
    [No Abstract]   [Full Text] [Related]  

  • 60. [Re-administration of drotrecogin alfa activated in a patient with episodes of severe sepsis].
    Verdú MT; Sánchez OJ
    Rev Esp Anestesiol Reanim; 2007 Dec; 54(10):637-8. PubMed ID: 18201006
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.